|Assessment Status||Rapid Review complete|
|Indication||Treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.|
|Rapid review commissioned||09/08/2013|
|Rapid review completed||18/09/2013|
|Rapid review outcome||At the current price a full HTA would be required.|
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.